VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | Treatment options for high-risk AML

Nigel Russell, MD, Guy’s Hospital NHS Trust, London, UK, talks on attempts to improve treatment options for younger patients with high-risk acute myeloid leukemia (AML). Specifically discussed is the UK NCRI AML17 trial (ISRCTN55675535), comparing FLAG-Ida and daunorubicin with clofarabine for high-risk AML. Prof. Russell highlights the importance of early recognition of high-risk disease and reveals that optimizing induction and pre-stem cell transplant treatment allows more patients to get to transplant in remission. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter